More importantly, B55α mutation appears to sensitize leukemia cells to MK2206 but ablate response to FTY720 and may represent a potential biomarker for evaluating targeted therapy and individualized medicine in AML. Here, PPP2R2A is linked to acute myeloid leukemia.